Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific Chimeric Antigen Receptor (CAR) T Cells”

38 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 38 results

Early research (Phase 1)Not Yet RecruitingNCT07335328
What this trial is testing

Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

Who this might be right for
B-cell Non Hodgkin Lymphoma
Medical College of Wisconsin 24
Early research (Phase 1)UnknownNCT03706547
What this trial is testing

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma Progression
Peng Liu 20
Early research (Phase 1)WithdrawnNCT03605238
What this trial is testing

Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20

Who this might be right for
Neuromyelitis Optica Spectrum Disorder
Chinese PLA General Hospital
Testing effectiveness (Phase 2)Active Not RecruitingNCT04697940
What this trial is testing

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Who this might be right for
Relapsed and Refractory B-cell Non-Hodgkin's LymphomaDecitabine-primed Tandem CD19/CD20 CAR T Cells
Han weidong 33
Testing effectiveness (Phase 2)UnknownNCT03185494
What this trial is testing

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Who this might be right for
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+20 more
Chinese PLA General Hospital 30
Very early researchUnknownNCT04303247
What this trial is testing

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

Who this might be right for
B-cell Lymphoma RefractoryB-cell Lymphoma Recurrent
Xinqiao Hospital of Chongqing 30
Testing effectiveness (Phase 2)Study completedNCT03097770
What this trial is testing

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Who this might be right for
Hematopoietic/Lymphoid CancerAdult Acute Lymphoblastic Leukemia in RemissionB-cell Adult Acute Lymphoblastic Leukemia+20 more
Chinese PLA General Hospital 100
Very early researchUnknownNCT05225831
What this trial is testing

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
CD19+ and CD 22+ B-ALL
Hebei Senlang Biotechnology Inc., Ltd. 100
Testing effectiveness (Phase 2)Looking for participantsNCT07461831
What this trial is testing

CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma

Who this might be right for
Large B-Cell Lymphoma (LBCL)
Beijing Tongren Hospital 100
Early research (Phase 1)UnknownNCT03271515
What this trial is testing

Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

Who this might be right for
LeukemiaLymphoma
Beijing Doing Biomedical Co., Ltd. 20
Early research (Phase 1)UnknownNCT04303520
What this trial is testing

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

Who this might be right for
CD19-positive ALL
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine 20
Not applicableLooking for participantsNCT07309497
What this trial is testing

Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)

Who this might be right for
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaCART TherapyBispecific Antibody+1 more
University of Zurich 208
Early research (Phase 1)UnknownNCT05523661
What this trial is testing

Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients

Who this might be right for
Ph Positive ALLCAR-T CellDasatinib
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 15
Testing effectiveness (Phase 2)Looking for participantsNCT06503094
What this trial is testing

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

Who this might be right for
B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 80
Early research (Phase 1)Looking for participantsNCT06285279
What this trial is testing

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

Who this might be right for
Lupus NephritisANCA-associated VasculitisMembranous Nephropathy - PLA2R Induced+1 more
Nanjing University School of Medicine 24
Early research (Phase 1)Not Yet RecruitingNCT07166549
What this trial is testing

Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

Who this might be right for
B Cell MalignanciesB-cell LeukemiaB Cell Lymphoma+2 more
University Hospital, Basel, Switzerland 12
Testing effectiveness (Phase 2)Looking for participantsNCT04186520
What this trial is testing

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Who this might be right for
Non Hodgkin Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)+5 more
Medical College of Wisconsin 100
Early research (Phase 1)UnknownNCT04662099
What this trial is testing

T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma

Who this might be right for
CS1+ or BCMA+ Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 24
Testing effectiveness (Phase 2)Looking for participantsNCT07523529
What this trial is testing

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

Who this might be right for
Advanced UnresectableMetastatic
Beijing Biotech 72
Very early researchEnded earlyNCT04034446
What this trial is testing

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 2
Load More Results